Shuyu Dan Li

Dan Li’s primary research interests focus on applying genomics, genetics and integrative data analysis to further our understanding of disease mechanisms and to develop biomarkers for personalized medicine.  Dan received his Ph.D. in Cell & Molecular Biology from University of Texas Southwestern Medical Center at Dallas, and a M.S. in Computer Sciences from University of Texas at Dallas.  Prior to Mount Sinai, Dan made significant contributions to delineating novel oncogenic pathways in hepatocellular carcinomas (HCCs) through whole genome sequencing and integrative genomic data analysis, which led to several seminal publications on Nature Genetics and Genome Research.  He also developed a predictive biomarker for a standard care drug for non-small cell lung cancer based on a bioinformatics approach. The marker was subsequently validated in clinic and a patent application was filed where Dan was named as a co-inventor.  Dan is well published (selected publication) and served on National Cancer Institute Special Emphasis Panel on Integrative Cancer Biology Program and Center for Cancer Systems Biology.